1. Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 1996;348:1535-41.
2. Tonino RP, Meunier PJ, Emkey R, Rodriguez-Portales JA, Menkes CJ, Wasnich RD, et al. Skeletal benefits of alendronate: 7-year treatment of postmenopausal osteoporotic women. J Clin Endocrinol Metab 2000;85:3109-15.
3. Kwek EB, Goh SK, Koh JS, Png MA, Howe TS. An emerging pattern of subtrochanteric stress fractures: a long-term complication of alendronate therapy? Injury 2008;39:224-31.
4. Goh SK, Yang KY, Koh JS, Wong MK, Chua SY, Chua DT, et al. Subtrochanteric insufficiency fractures in patients on alendronate therapy: a caution. J Bone Joint Surg Br 2007;89:349-53.
5. Sayed-Noor AS, Sjödén GO. Case reports: two femoral insufficiency fractures after long-term alendronate therapy. Clin Orthop Relat Res 2009;467:1921-6.
6. Cermak K, Shumelinsky F, Alexiou J, Gebhart MJ. Case reports: subtrochanteric femoral stres fractures after prolonged alendronate therapy. Clin Orthop Relat Res 2010;468:1991-6.
7. Likert R. A technique for measurement of attitudes. Arch Psychol 1932;140:44-60.
8. Fleisch H. Bisphosphonates: mechanisms of action. Endocr Rev 1998; 19:80-100.
9. Odvina CV, Zerwekh JE, Rao DS, Maalouf N, Gottschalk FA, Pak CYY. Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab 2005;90:1294–301.
10. Mashiba T, Turner CH, Hirano T, Forwood MR, Johnston CC, Burr DB. Effects of suppressed bone turnover by bisphosphonates on microdamage accumulation and biomechanical properties in clinically relevant skeletal sites in beagles. Bone 2001;28:524-31.
11. Çevikol A, Umay E, Karaahmet ÖZ Avluk ÖÇ, Çakcı A. Osteoporozlu hastalarda bifosfonatların devamlı veya aralıklı kullanımının kırık, kemik yoğunluğu ve biyokimyasal parametrelere etkisi. Türkiye Osteoporoz Dergisi 2010;16:1-8.
12. Black DM, Schwartz AV, Ensrud KE, Cauley JA, Levis S, Quandt SA, et. al. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA 2006;27;296:2927-38
13. Black DM, Kelly MP, Genant HK, Palermo L, Eastell R, Bucci-Rechtweg C, et al. Bisphosphonates and fractures of the subtrochanteric or diaphyseal femur. N Engl J Med 2010;13;362:1761-71.